IMM 124E

Drug Profile

IMM 124E

Alternative Names: Anti-LPS colostrum (Imm124-E) - Immuron; Bovine colostrum; Hyper-immune bovine colostrum powder (BCP) for NASH - Immuron; IMM-124E; IMM122-I

Latest Information Update: 25 Jul 2016

Price : $50

At a glance

  • Originator Immuron
  • Developer Hadassah Medical Organization; Immuron; La Trobe University; University of Melbourne; Virginia Commonwealth University
  • Class Antibodies; Polyclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Alcoholic hepatitis; Non-alcoholic steatohepatitis
  • Preclinical Autistic disorder
  • No development reported Metabolic syndrome

Most Recent Events

  • 20 Jul 2016 Preclinical trials in Autistic disorder in Australia (unspecified route)
  • 15 Mar 2016 Biomarkers information updated
  • 18 Nov 2015 Interim adverse events data from a phase II trial in Non-alcoholic steatohepatitis released by Immuron
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top